Company News

PharmaJet’s Stratis® Needle-Free Injector Receives WHO PQS Certification as a Pre-qualified Delivery Device for Vaccine Administration

GOLDEN, Colo. – Feb. 20, 2013 – PharmaJet Inc. has become the first and only needle-free injection company to receive Performance, Quality and Safety (PQS) pre-qualified certification from the World Health Organization (WHO). Details

PharmaJet Enters into Strategic Collaboration with CSL Limited for Needle‐free Delivery of Influenza Vaccines

GOLDEN, Colo. ‐ Nov. 29, 2012 – PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria® influenza vaccine to be delivered with the PharmaJet Stratis® needle‐free jet injector, as soon as the 2013‐2014 flu season. Details

2011 Colorado Companies to Watch Winner

GOLDEN, Colo. – June 30, 2011 – Now in its third year, Colorado Companies to Watch attracted over 360 nominees. With nearly 100 companies selected as finalists, PharmaJet prevailed along with 49 others to receive the distinction of... Details

Ernst & Young Entrepreneur Of The Year 2011

Golden, CO – May 23, 2011 – PharmaJet® today announced that Chairman, Heather Callender-Potters is an Ernst & Young Entrepreneur Of The Year® 2011 finalist. Details

FDA Grants PharmaJet 510(k) Clearance on Intradermal Needle-Free Injection Device

GOLDEN, Colo. – March 22, 2011 – The U.S. Food and Drug Administration (FDA) has awarded PharmaJet 510(k) clearance to market a 0.1mL Intradermal (ID) Needle-free Injection System. Details

CDC Awards Contract to PharmaJet® for Development of Needle‐Free Intradermal Vaccine Delivery Device

GOLDEN, Colo. – Jan. 27, 2011 – The Centers for Disease Control (CDC) has awarded PharmaJet with a substantial grant to develop needle-free injection devices for intradermal (ID) vaccine delivery. Details

PharmaJet and USAMRIID Enter Collaboration

Golden, Colo. — Dec. 6, 2010 – A Cooperative Research and Development Agreement (CRADA) has been signed between PharmaJet, Inc. and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to utilize the PharmaJet needle-free jet injection delivery technology in conjunction with USAMRIID’s candidate gene-based smallpox vaccine. Details

Inviragen and PharmaJet Receive $15.5 Million NIAID Contract

Fort Collins, Colo., and Golden, Colo. — Oct. 12, 2010 – Inviragen and PharmaJet announced the award of a five-year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of a needle-free, easy-to-administer dengue vaccine. Details